Morgan Stanley’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Morgan Stanley’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,900	Closed	-$39K	–	8020
2022 Q3	$39K	Hold	3,900	–	–	﹤0.01%	6524
2022 Q2	$39K	Hold	3,900	–	–	﹤0.01%	6723
2022 Q1	$38K	Hold	3,900	–	–	﹤0.01%	6839
2021 Q4	$38K	Hold	3,900	–	–	﹤0.01%	6939
2021 Q3	$38K	Hold	3,900	–	–	﹤0.01%	6837
2021 Q2	$38K	Buy	+3,900	New	+$38.4K	﹤0.01%	6782

Other funds holding EUCR

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley's EUCR Position: Q4 2022 in Review

Morgan Stanley sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q4 2022, closing a stake of 3,900 shares — an estimated $39K sold.

Morgan Stanley first reported a position in EUCR in Q2 2021 and held it in 6 quarters. The position peaked at $39K in Q3 2022. 5 funds tracked by Wall St. Rank hold EUCR as of Q4 2022.

Morgan Stanley reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Morgan Stanley sold 3,900 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q4 2022, an estimated $39K.
Morgan Stanley first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q2 2021 and held it in 6 quarters.
Morgan Stanley's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $39K in Q3 2022.
5 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q4 2022.

Based on Morgan Stanley's 13F filing for Q4 2022, filed 14 Feb 2023.